SWS Partners acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,821 shares of the healthcare product maker’s stock, valued at approximately $104,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Keel Point LLC lifted its position in Abbott Laboratories by 2.2% in the second quarter. Keel Point LLC now owns 13,580 shares of the healthcare product maker’s stock worth $660,000 after purchasing an additional 294 shares during the period. Simmons Bank lifted its position in Abbott Laboratories by 1.5% in the second quarter. Simmons Bank now owns 23,978 shares of the healthcare product maker’s stock worth $1,166,000 after purchasing an additional 343 shares during the period. Hutner Capital Management Inc. lifted its position in Abbott Laboratories by 1.0% in the second quarter. Hutner Capital Management Inc. now owns 42,298 shares of the healthcare product maker’s stock worth $2,056,000 after purchasing an additional 411 shares during the period. South Texas Money Management Ltd. lifted its position in Abbott Laboratories by 5.7% in the second quarter. South Texas Money Management Ltd. now owns 8,195 shares of the healthcare product maker’s stock worth $398,000 after purchasing an additional 444 shares during the period. Finally, National Asset Management Inc. lifted its position in Abbott Laboratories by 2.4% in the second quarter. National Asset Management Inc. now owns 20,413 shares of the healthcare product maker’s stock worth $993,000 after purchasing an additional 473 shares during the period. Institutional investors and hedge funds own 72.34% of the company’s stock.
Shares of NYSE:ABT opened at $59.27 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.86 and a current ratio of 2.26. Abbott Laboratories has a 12-month low of $42.31 and a 12-month high of $64.60. The firm has a market cap of $102,143.08, a price-to-earnings ratio of 23.40, a PEG ratio of 1.73 and a beta of 1.49.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 1.89%. The ex-dividend date is Thursday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 44.80%.
In other Abbott Laboratories news, insider Brian J. Blaser sold 27,733 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $62.26, for a total transaction of $1,726,656.58. Following the sale, the insider now directly owns 156,587 shares of the company’s stock, valued at approximately $9,749,106.62. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Stephen R. Fussell sold 13,313 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $62.84, for a total transaction of $836,588.92. Following the sale, the executive vice president now directly owns 152,343 shares in the company, valued at $9,573,234.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 124,261 shares of company stock worth $7,559,987. Company insiders own 0.74% of the company’s stock.
A number of equities research analysts have weighed in on ABT shares. Bank of America upped their target price on Abbott Laboratories from $60.00 to $70.00 in a research report on Wednesday, January 24th. They noted that the move was a valuation call. Royal Bank of Canada restated a “buy” rating and issued a $67.00 target price on shares of Abbott Laboratories in a research report on Thursday, January 25th. Stifel Nicolaus upped their target price on Abbott Laboratories from $63.00 to $71.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Barclays restated a “buy” rating and issued a $66.00 target price on shares of Abbott Laboratories in a research report on Monday, January 8th. Finally, Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Tuesday, January 2nd. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $65.47.
TRADEMARK VIOLATION NOTICE: This story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2018/04/17/sws-partners-takes-104000-position-in-abbott-laboratories-abt.html.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.